- Home
- YHNA vs BEAT Comparison
YHNA vs BEAT Comparison
Compare YHNA & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHNA
- BEAT
- Stock Information
- Founded
- YHNA 2023
- BEAT 2015
- Country
- YHNA Hong Kong
- BEAT United States
- Employees
- YHNA N/A
- BEAT 20
- Industry
- YHNA
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- YHNA
- BEAT Technology
- Exchange
- YHNA Nasdaq
- BEAT Nasdaq
- Market Cap
- YHNA 79.9M
- BEAT 74.1M
- IPO Year
- YHNA 2024
- BEAT 2021
- Fundamental
- Price
- YHNA $10.04
- BEAT $2.68
- Analyst Decision
- YHNA
- BEAT Buy
- Analyst Count
- YHNA 0
- BEAT 1
- Target Price
- YHNA N/A
- BEAT $8.00
- AVG Volume (30 Days)
- YHNA 10.8K
- BEAT 282.2K
- Earning Date
- YHNA 01-01-0001
- BEAT 11-07-2024
- Dividend Yield
- YHNA N/A
- BEAT N/A
- EPS Growth
- YHNA N/A
- BEAT N/A
- EPS
- YHNA N/A
- BEAT N/A
- Revenue
- YHNA N/A
- BEAT N/A
- Revenue This Year
- YHNA N/A
- BEAT N/A
- Revenue Next Year
- YHNA N/A
- BEAT N/A
- P/E Ratio
- YHNA N/A
- BEAT N/A
- Revenue Growth
- YHNA N/A
- BEAT N/A
- 52 Week Low
- YHNA $9.99
- BEAT $1.06
- 52 Week High
- YHNA $10.05
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- YHNA N/A
- BEAT 47.14
- Support Level
- YHNA N/A
- BEAT $2.28
- Resistance Level
- YHNA N/A
- BEAT $3.48
- Average True Range (ATR)
- YHNA 0.00
- BEAT 0.29
- MACD
- YHNA 0.00
- BEAT -0.05
- Stochastic Oscillator
- YHNA 0.00
- BEAT 37.83
About YHNA YHN Acquisition I Limited Ordinary Shares
YHN Acquisition I Ltd is a newly organized blank check company for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all of the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses or entities.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.